Is there a generic for Symtuza?
No, no generic version of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is available. Symtuza, approved by the FDA in 2018 for HIV treatment, remains under patent protection with exclusivity until at least 2032-2033, blocking generic entry.[1][2]
When does Symtuza's patent expire?
Key patents covering Symtuza's formulation and combination expire between 2032 and 2037, including U.S. Patent No. 9,539,236 (expires May 2033) for the fixed-dose combo and others tied to Janssen's darunavir. Pediatric exclusivity adds six months, pushing full market access to around mid-2033.[2][3]
Are there authorized generics or alternatives?
Janssen has not released an authorized generic. HIV treatment guidelines recommend alternatives like Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) or generics for older regimens such as Truvada (emtricitabine/tenofovir disoproxil), available since 2020 at lower costs.[1][4]
Why no generics yet despite HIV drug competition?
Symtuza's multi-drug combo requires proving bioequivalence for all components, delaying ANDA approvals. Ongoing Paragraph IV challenges exist, but none have succeeded to date.[2]
What about biosimilars or future generics?
Symtuza is a small-molecule combo, not a biologic, so generics (not biosimilars) apply. First generics could launch post-2033 if no further extensions, though Janssen litigation has blocked earlier challengers.[2][3]
[1]: FDA Orange Book, https://www.accessdata.fda.gov/scripts/cder/ob/
[2]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/SYMTUZA
[3]: USPTO Patent Database, https://patents.google.com/patent/US9539236
[4]: DHHS HIV Guidelines, https://clinicalinfo.hiv.gov/en/guidelines